http://bionews-tx.com/news/2014/01/27/ut-health-science-center-san-antonio-researcher-receives-grant-to-fight-ovarian-cancer/
A researcher at the University of Texas Health Science Center at San Antonio is working on a new treatment for ovarian cancer by seeking a way to turn the body’s own defenses on the disease, one of the deadliest of all cancers.
Currently an immunologist at the UT Health Science Center, Dr. Tyler Curiel has received a $900,00 grant from the Ovarian Cancer Research Foundation in support for her research. Curiel’s group will develop a multi-modal immune therapy for ovarian cancer using approaches in three key areas: first, they will reduce immune impediments to effective ovarian cancer immunotherapy; the team will then block molecular mechanisms that drive tumor growth and inhibit anti-tumor immunity; finally, they use new-generation adoptive T cell (a type of lymphocyte that plays a central role in cell-mediated immunity) transfers.
Curiel is also a professor at the Health Science Center’s School of Medicine. He has won a separate grant has been selected to participate in an ambitious multimillion-dollar international effort to develop a new drug that could be used to fight an array of cancers.
His current program has three highly integrated and interactive projects, led by four ovarian cancer thought leaders, who will work to identify optimal approaches in these three key areas and means to combine them for maximal clinical effects.
“Our program will allow development of a major grant to test approaches clinically, first in resistant cancers, and later in relapse prevention and as treatment after failure of front-line therapy,” Curiel said.
Curiel is also a professor at the Health Science Center’s School of Medicine. He has won a separate grant has been selected to participate in an ambitious multimillion-dollar international effort to develop a new drug that could be used to fight an array of cancers.
His current program has three highly integrated and interactive projects, led by four ovarian cancer thought leaders, who will work to identify optimal approaches in these three key areas and means to combine them for maximal clinical effects.
“Our program will allow development of a major grant to test approaches clinically, first in resistant cancers, and later in relapse prevention and as treatment after failure of front-line therapy,” Curiel said.
